Retireful LLC Acquires New Holdings in Organon & Co. (NYSE:OGN)

Retireful LLC bought a new position in Organon & Co. (NYSE:OGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 12,529 shares of the company’s stock, valued at approximately $187,000.

A number of other large investors have also added to or reduced their stakes in the stock. Barclays PLC grew its stake in shares of Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after purchasing an additional 84,136 shares during the period. Public Sector Pension Investment Board boosted its holdings in shares of Organon & Co. by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company’s stock worth $11,713,000 after buying an additional 41,954 shares during the last quarter. Weiss Asset Management LP bought a new stake in Organon & Co. during the third quarter valued at approximately $32,966,000. Cerity Partners LLC increased its holdings in Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock valued at $12,766,000 after buying an additional 323,308 shares during the last quarter. Finally, Beddow Capital Management Inc. raised its position in Organon & Co. by 38.8% in the third quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock worth $5,867,000 after acquiring an additional 85,775 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 2.6 %

Shares of Organon & Co. stock opened at $15.77 on Friday. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The company’s fifty day simple moving average is $15.32 and its 200-day simple moving average is $18.24. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock has a market capitalization of $4.06 billion, a PE ratio of 3.13, a P/E/G ratio of 0.86 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co.’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 earnings per share. As a group, equities analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.10%. The ex-dividend date was Tuesday, November 12th. Organon & Co.’s dividend payout ratio is 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.